Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART Use of Biologics in Chronic Rhinosinusitis With Nasal Polyposis
NCT06824649Phase 4Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Jun 2026
- Primary completion
- Feb 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Dupilumab, Omalizumab and Mepolizumab (3 arms). Primary endpoint: Disease-Specific Quality of Life at 24 weeks. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06824649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824649.